Search 

Dear Prospect Customer:

I would like to introduce my company (TDM Pharmaceutical Research, Inc) to you. TDM Pharmaceutical Research, INC, is a highly productive, intensely focused, quality-oriented CRO; we are experienced, well established, and driven by scientific merit. As a full-service GLP and GCP compliant laboratory, TDM offers a variety of discovery, research, development, bioanalytical, and consulting services to support discovery and development of pharmaceutical and chemical products. We pride ourselves on prompt data turnaround and addressing our clients’ needs with the accuracy and quality that are critical to their businesses.

TDM is uniquely different from other CROs: our over 90 years of combined industry experience allows us to resolve complex issues by providing comprehensive solutions in pharmacokinetics, toxicokinetics, pharmacokinetic/pharmacodynamic correlations, and more.

We are experienced in both the sponsor and the CRO position, so we anticipate and address the needs of our clients. Resourceful, committed personnel provide proactive support throughout each project, and respond to potential issues immediately.

Our myriad clients include both companies and individuals in the pharmaceutical and related industries. By selecting TDM as the partner for your next project, you will find we take each job and its needs personally; our focus is always on the client!

If you have any question, please feel free to contact me at: changfu.cheng@tdmrxresearch.com, or phone at 1-774-258-2425.

Thanks!

Changfu Cheng, PhD

President

TDM Pharmaceutical Research, Inc

https://tdmpharmalab.com

About TOT BIOPHARM International Company Limited
(HKG:1875)

TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.

The Group has in place three major integrated technology platforms:

Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;

Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;

Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.

Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.